The POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). The company is developing its lead candidate SER-252 for advanced Parkinson's disease in a Phase 1b registrational trial aligned with an FDA 505(b)(2) NDA pathway.
Cyborg Score Rationale
The company received a NYSE deficiency notice for failing to meet listing criteria with stockholders' equity below $2 million and losses in 3 of its most recent 4 years. However, it submitted a complete response to an FDA clinical hold in December 2025 addressing excipient safety concerns.
Top Insights
First patient enrolled in Phase 1b registrational trial of SER-252 for advanced Parkinson's disease in February 2026
Stockholders' equity of only $1.6 million as of September 30, 2025, with losses in three of four recent fiscal years
Secured convertible financing up to $20M with $5M drawn and ATM program generating $2.8M in net proceeds as of Q3 2025
Appointed Joshua Thomas as Vice President and Head of Chemistry in December 2025 to optimize POZ-based candidates
Named Competitors
Levodopa-based therapies and dopamine agonists — Standard-of-care Parkinson's disease treatments
Advanced neurological drug development platforms — Competing POZ-like delivery technologies for neurological indications
Recent Developments
(February 2026) First patient enrolled in Phase 1b registrational trial of SER-252 for advanced Parkinson's disease
(December 2025) Submitted complete response to FDA clinical hold addressing trehalose excipient formulation questions
(December 2025) Appointed Joshua Thomas, Ph.D., as Vice President and Head of Chemistry
(November 2025) FDA placed clinical hold on SER-252 IND, later lifted after submission of additional data
Open the full interactive Serina Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.